Medifast, Inc. (MED)

NYQ – Real Time Price. Currency in USD

12.57

+0.17 (1.37%)

At close: May 12, 2026, 4:00 PM EDT

12.57

0.00 (0.00%)

Pre-market: May 13, 2026, 5:38 AM EDT

13.05.2026

Why Medifast's $15 Cash Per Share Makes It A Strong Buy

Medifast trades below net cash value, with $15 per share in cash versus a $12.60 share price, creating a compelling value floor. Coach productivity surged 19% YoY to $5,432 per coach, signaling early signs of operational turnaround despite a shrinking coach base. Cost-cutting initiatives, asset sales, and a positive operating cash flow position MED for potential profitability by Q4 2026, with a $30 million savings target.

12.05.2026

Medifast: Worth Putting On A Watchlist

Medifast has continued to report concerning financials. A shrinking coach network lowers revenues, and costs remain too high. A turnaround can't be written off quite yet. MED's coach productivity has improved clearly, and a shift to a metabolic health focus from weight loss could work out. Negative enterprise value clearly implies upside potential; I estimate 47% upside to $18.50 if the company's earnings stabilize over the mid-term. Such upside is speculative, though.

05.05.2026

Medifast Q1 Loss Narrower Than Expected, Revenues Decline Y/Y

MED beats first-quarter estimates despite steep revenue declines, while stronger coach productivity and a new product launch support recovery hopes.

04.05.2026

Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript

04.05.2026

Medifast (MED) Reports Q1 Loss, Tops Revenue Estimates

Medifast (MED) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.11 per share a year ago.

04.05.2026

Medifast Announces First Quarter 2026 Financial Results

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue of $76.0 million, with revenue per active earning coach of $5,432 Independent active earning coaches of 14,000 Net loss of $2.1 million, or $0.19 per diluted share ("EPS") Cash, Cash Equivalents, and Investment Securities of $168.9 million with no debt.

01.05.2026

Medifast's Q1 Earnings on The Horizon: Key Insights for Investors

MED reports Q1 fiscal 2026 May 4; revenue seen down 36.3% and EPS at a 55-cent loss as coach base and demand stay pressured.

Videos

No Data

There is no data to display

Press releases

04.05.2026

Medifast Announces First Quarter 2026 Financial Results

14.04.2026

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Medifast, Inc. (NYSE: MED)

NEW YORK, April 14, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Medifast, Inc. (NYSE: MED) on behalf of the company's shareholders. The investigation seeks to determine whether Medifast's directors breached their fiduciary duties in connection with recent corporate actions.

20.03.2026

Medifast Announces Cooperation Agreement with Steamboat Capital

BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today announced the company's Board of Directors has agreed to nominate Parsa Kiai and Jeff Rose from Steamboat Capital Partners LLC as independent director candidates to stand for election at the company's 2026 Annual Meeting of Stockholders, which is provisionally scheduled for May 19, 2026. These nominations are pursuant to a Cooperati.

20.02.2026

Scientific Evidence Demonstrates OPTAVIA®'s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients

BALTIMORE--(BUSINESS WIRE)--As part of its continued focus on improving metabolic health, Medifast® (NYSE: MED) today announced that OPTAVIA's comprehensive metabolic health system is available for reimbursement on select insurance plans using Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). OPTAVIA clients may be able to save up to 40% on program costs by working with their medical provider and insurance administrator to use pre-tax medical funds, offering accessibility for.

Medifast, Inc. (MED)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Medifast, Inc. (MED)

Why Medifast's $15 Cash Per Share Makes It A Strong Buy

Medifast: Worth Putting On A Watchlist

Medifast Q1 Loss Narrower Than Expected, Revenues Decline Y/Y

Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript

Medifast (MED) Reports Q1 Loss, Tops Revenue Estimates

Medifast Announces First Quarter 2026 Financial Results

Medifast's Q1 Earnings on The Horizon: Key Insights for Investors

Videos

No Data

Press releases

Medifast Announces First Quarter 2026 Financial Results

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Medifast, Inc. (NYSE: MED)

Medifast Announces Cooperation Agreement with Steamboat Capital

Scientific Evidence Demonstrates OPTAVIA®'s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients

Why Medifast's $15 Cash Per Share Makes It A Strong Buy

Medifast: Worth Putting On A Watchlist

Medifast Q1 Loss Narrower Than Expected, Revenues Decline Y/Y

Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript

Medifast (MED) Reports Q1 Loss, Tops Revenue Estimates

Medifast Announces First Quarter 2026 Financial Results

Medifast's Q1 Earnings on The Horizon: Key Insights for Investors

Videos

No Data

Press releases

Medifast Announces First Quarter 2026 Financial Results

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Medifast, Inc. (NYSE: MED)

Medifast Announces Cooperation Agreement with Steamboat Capital

Scientific Evidence Demonstrates OPTAVIA®'s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients

Search stocks

Medifast, Inc. (MED)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Medifast, Inc. (MED)

Why Medifast's $15 Cash Per Share Makes It A Strong Buy

Medifast: Worth Putting On A Watchlist

Medifast Q1 Loss Narrower Than Expected, Revenues Decline Y/Y

Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript

Medifast (MED) Reports Q1 Loss, Tops Revenue Estimates

Medifast Announces First Quarter 2026 Financial Results

Medifast's Q1 Earnings on The Horizon: Key Insights for Investors

Videos

No Data

Press releases

Medifast Announces First Quarter 2026 Financial Results

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Medifast, Inc. (NYSE: MED)

Medifast Announces Cooperation Agreement with Steamboat Capital

Scientific Evidence Demonstrates OPTAVIA®'s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients

Why Medifast's $15 Cash Per Share Makes It A Strong Buy

Medifast: Worth Putting On A Watchlist

Medifast Q1 Loss Narrower Than Expected, Revenues Decline Y/Y

Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript

Medifast (MED) Reports Q1 Loss, Tops Revenue Estimates

Medifast Announces First Quarter 2026 Financial Results

Medifast's Q1 Earnings on The Horizon: Key Insights for Investors

Videos

No Data

Press releases

Medifast Announces First Quarter 2026 Financial Results

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Medifast, Inc. (NYSE: MED)

Medifast Announces Cooperation Agreement with Steamboat Capital

Scientific Evidence Demonstrates OPTAVIA®'s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients